Summary:
- Vima Therapeutics, a biotechnology company based in Cambridge, MA, secured $60M in Series A funding led by Atlas Venture.
- The company plans to use the funds to expand operations and advance their oral therapy for dystonia and related movement disorders.
- Vima Therapeutics is currently conducting a Phase 1 clinical trial for their potential first-in-class oral therapy, with plans to move into Phase 2 by the end of 2025.
Article:
Vima Therapeutics, a clinical-stage biotechnology company headquartered in Cambridge, MA, has successfully raised $60 million in Series A funding, with Atlas Venture taking the lead on the investment along with participation from Access Industries and Canaan. This financial boost will enable the company to expand its operations and further its research and development efforts in the field of dystonia and related movement disorders.
Under the leadership of CEO and Founder Bernard Ravina, Vima Therapeutics is dedicated to providing innovative treatments for patients suffering from dystonia by targeting the root cause of the disease. Their primary focus is on advancing an oral therapy, known as VIM0423, which is currently undergoing a Phase 1 clinical trial. The company aims to initiate Phase 2 of the trial by the fourth quarter of 2025, with the goal of improving movement control for individuals affected by dystonia.
The executive team at Vima Therapeutics brings a wealth of experience to the table, including Judith Dunn, PhD, who serves as the president and head of R&D with over 30 years of drug development expertise, Jessica Fees as the chief financial officer, and Ariel D. Jasie, JD, as the chief business officer and general counsel, among others.
With a strong focus on advancing their oral therapy and providing groundbreaking solutions for patients with movement disorders, Vima Therapeutics is poised to make a significant impact in the biotechnology industry. Stay tuned for more updates on their progress as they continue to drive innovation in the field.
This article was originally published on FinSMEs on 30/05/2025.
